SathalapRx

SathalapRx is a preclinical-stage biotechnology company dedicated to developing novel therapeutic interventions for neurodegenerative diseases and aging-related conditions. The company's primary focus is on the modulation of autophagy, a critical cellular process for degrading and recycling damaged proteins and organelles. By leveraging its proprietary platform to identify and optimize small molecule activators of autophagy, SathalapRx aims to address the underlying protein aggregation and cellular dysfunction characteristic of diseases like Parkinson's and Alzheimer's. The company is currently advancing several discovery-stage programs targeting specific components of the autophagy pathway to restore proteostasis and promote neuronal health.